Ci Circulating t g tumor or D DNA e A expos osure i in p - - PowerPoint PPT Presentation

▶
ci circulating t g tumor or d dna e a expos osure i in p
SMART_READER_LITE
LIVE PREVIEW

Ci Circulating t g tumor or D DNA e A expos osure i in p - - PowerPoint PPT Presentation

Jan 14, 2023 142 likes •318 views

Ci Circulating t g tumor or D DNA e A expos osure i in p peripheral b blood ood using a novel process: Early y results of a liquid biopsy y feasibility y study J Douissard 1 , F Ris 1 , M Hellan 2 , J Ouellette 2 , NC Buchs 1 , L

slide-1
SLIDE 1

J Douissard1, F Ris1, M Hellan2, J Ouellette2, NC Buchs1, L Buehler1, F Triponez1, C Toso1

1Geneva University Hospital and Medical School, Geneva, Switzerland 2 Wright State University, Ohio, USA

Ci Circulating t g tumor

  • r D

DNA e A expos

  • sure i

in p peripheral b blood

  • od

using a novel process: Early y results of a liquid biopsy y feasibility y study

slide-2
SLIDE 2

§ Non-financial aid from Intuitive Surgical Inc. § Research grant from Intuitive Surgical Inc. § Consulting for Verb Surgical Inc.

DISCLOSURES

slide-3
SLIDE 3

BACKGROUND: RELEVANT CANCER MORTALITY WITH STAGE AT DIAGNOSIS

5-years-survival - SEER1 database

1 Surveillance, Epidemiology and End Results

database, National Institute of Health, USA

slide-4
SLIDE 4

BACKGROUND: SCREENING LIMITATIONS

slide-5
SLIDE 5

BACKGROUND: LIQUID BIOPSY - PRINCIPLES

slide-6
SLIDE 6

BACKGROUND: LIQUID BIOPSY – A WORKING CONCEPT

GUARDANT 360 FOUNDATION ONE LIQUID

  • Commercially available
  • Lower sensitivity essays targeted at

later stage cancers

  • Tumor genotyping for treatment

information

QUANTGENE PLATFORM

  • In development
  • Revolutionized Technology Stack
  • Panel of > 200 genes & > 70 000

locations

  • Aiming at the highest possible accuracy

to accommodate wide early cancer detection

slide-7
SLIDE 7

METHODS: THE QUANTGENE PLATFORM

slide-8
SLIDE 8

METHODS: DRAWING THE CUTOFF

Probability score Patient

1 10 100 1000 2 4 6 8 10 12 14 16 18 20

slide-9
SLIDE 9

METHODS: DRAWING THE CUTOFF

Probability score Patient

1 10 100 1000 2 4 6 8 10 12 14 16 18 20

slide-10
SLIDE 10

METHODS: DRAWING THE CUTOFF

1 10 100 1000 2 4 6 8 10 12 14 16 18 20

Probability score Patient

slide-11
SLIDE 11

METHODS: STUDY DESIGN

slide-12
SLIDE 12

PATIENTS ENROLLMENT

RESULTS

Enrolled to date: Total: 2944 Cancer: 942 Controls: 2002 Processed with Quantgene Technology: Total: 154 Cancer: 67 Controls: 87 Samples analyzed: Total: 132 Cancer: 56 Colorectal: 33 Pancreas: 23 Controls: 76 22 samples excluded

slide-13
SLIDE 13

STAGE SPECIFIC SENSITIVITY: COLORECTAL CANCER

Tumor Stage Patients (n) Correctly identified individuals (n) Stage specific sensitivity (%) I II III IV Not applicable/Unknown Total 6 6 13 6 2 33 6 6 11 6 1 30 100 100 84.6 100 50 90.9

RESULTS

slide-14
SLIDE 14

STAGE SPECIFIC SENSITIVITY: PANCREATIC CANCER

Tumor Stage Patients (n) Correctly identified individuals (n) Stage specific sensitivity (%) I II III IV Not applicable/Unknown Total 2 6 8 5 2 23 2 6 7 5 1 21 100 100 87.5 100 50 91.3

RESULTS

slide-15
SLIDE 15

SPECIFICITY & OVERALL PERFORMANCE

RESULTS

Overall test sensitivity 91.1 Overall test specificity 94.7 Positive predictive value 93.0 Negative predictive value 93.5

Control patients (n) Correctly identified (n) Specificity (%) 76 72 94.7

slide-16
SLIDE 16

CONCLUSION: APPLICATIONS FOR SURGERY & BEYOND

slide-17
SLIDE 17

THANK YOU!

Jonathan.Douissard@hcuge.ch